UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

Filed by the Registrant  x

Filed by a Party other than the Registrant  ¨

Check the appropriate box:

 

¨	Preliminary Proxy Statement

 

¨	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨	Definitive Proxy Statement

 

x	Definitive Additional Materials

 

¨	Soliciting Material Pursuant to §240.14a-12

 

Protalix BioTherapeutics, Inc.

 

(Name of Registrant as Specified In Its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

x	No fee required.

 

¨	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

	1)	Title of each class of securities to which transaction applies:
	2)	Aggregate number of securities to which transaction applies:
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set
		forth the amount on which the filing fee is calculated and state how it was determined):
	4)	Proposed maximum aggregate value of transaction:
	5)	Total fee paid:

 

¨	Fee paid previously with preliminary materials.

 

¨	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:

 

	1)	Amount Previously Paid:
	2)	Form, Schedule or Registration Statement No:
	3)	Filing Party:
	4)	Date Filed:

 

 

 

 

Protalix Biotherapeutics Inc. Announces Adjournment of Annual Meeting

 

Protalix Biotherapeutics has announced that the April 15^th, 2018 Annual Meeting of Stockholders has been adjourned until May 13, 2018 to allow additional time for stockholders to submit their proxies in connection with the meeting.

 

Given the importance of the proposals on the agenda of the meeting, we want to ensure that all stockholders have sufficient time to have their vote represented. This adjournment will allow additional time for stockholders to vote on these proposals. The annual meeting is scheduled to reconvene on Sunday, May 13, 2018 at 1:00 pm IST at the office of our Israeli counsel, Horn & Co., Law Offices.

 

Our Annual Meeting of Stockholders is your opportunity to participate in the decision-making process of our company. In particular, your support of proposal 4 will permit our Board of Directors to increase the number of authorized shares of our common stock from 250 million to 350 million. The increase will provide our management the flexibility needed to raise the capital required to expand our pioneering work in biotherapeutics.

 

We urge our stockholders who have not yet executed their proxy to please do so. This will help save us further solicitation costs and ensure that your important vote is represented.

 

Please vote your shares of stock now so that your vote can be counted without delay. Voting is easy. You may use one of the options below to ensure that your vote is promptly recorded in time for the Annual Meeting:

 

§

VOTE BY TOUCH-TONE PHONE: You may cast your vote by calling the toll-free number on the enclosed proxy card. Follow the instructions on your proxy card to cast your vote.

 

§

VOTE VIA THE INTERNET: You may cast your vote by logging onto the website identified on the enclosed proxy card and following the instructions on the screen.

 

§

VOTE BY MAIL: You may cast your vote by mail by completing, signing, dating and mailing the enclosed proxy card in the postage-prepaid return envelope provided.

 

If you have any questions or require further assistance in voting your shares, please contact our proxy solicitor Alliance Advisors toll-free at 833-501-4837.

 

 

Sincerely,

 

Yossi Maimon

Chief Financial Officer

 

 

 

 

To our valued shareholder:

 

The annual meeting of stockholders of Protalix Biotherapeutics, Inc. has been adjourned and will now be held on May 13^th, 2018.

 

According to our records your account is still unvoted and as an investor your participation will help advance opportunities for the company.

 

The Board asks for your support on Proposal #4, which is intended to permit the company to increase the number of authorized shares of common stock from 250 million to 350 million.  By increasing the authorized shares, the Board and the company will be able to raise capital in the future, on terms and conditions that they believe to be reasonable, in order to allow the company to obtain funding to continue advancing its clinical programs.

 

For additional information please reference the 2018 Proxy Statement filed on SEC.gov:

 

https://www.sec.gov/Archives/edgar/data/1006281/000157104918000157/0001571049-18-000157-index.htm

 

Please call us today at 833-501-4837 in order to vote your account.